Question · from the living review of ACE Inhibitors and Angiotensin Receptor Blockers →

Is it true that ACEi and ARBs reduce all-cause mortality in heart failure with reduced ejection fraction?

Established updated weekly · as of

Priors rates this Established — 91 out of 100, updated weekly. Yes — this looks well established. On the claim that ACEi and ARBs reduce all-cause mortality in heart failure with reduced ejection fraction, its four-agent AI review panel weighs 6 primary peer-reviewed studies.

RefutedDoubtfulUncertainLikelyEstablished
where this sits on Priors’ scale of how settled the evidence is

How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.

The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full ACE Inhibitors and Angiotensin Receptor Blockers review.

Related Cardiovascular questions

Is it true that ACEi and ARBs slow progression of proteinuric chronic kidney disease? → Is it true that ACEi and ARBs reduce albuminuria and slow diabetic nephropathy progression? → Is it true that ACEi-induced angioedema is more frequent in Black patients? → Is it true that dual ACEi plus ARB therapy increases risk of hyperkalemia and acute kidney injury? →
Reflects the peer-reviewed evidence as of 17 July 2026 and updates as new studies land. AI can make mistakes. Not medical advice.